Private equity firms mull merger of older GSK, Sanofi brands: FT
(Reuters) – Private equity firms are mulling over a $10 billion plan to buy and merge older drug brands of Britain's GlaxoSmithKline and France's Sanofi , the Financial Times reported on Sunday, citing sources. U.S.-based KKR and Warburg Pincus were among the firms considering making bids for assets owned by GSK and Sanofi, the newspaper quoted several people familiar with the matter as saying. According to an internal document seen by Reuters in July, Sanofi held talks with listed and private equity firms in relation to the sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs. The FT quoted people close to the matter as saying that Blackstone , Advent, Apollo and Bain Capital were among the other private equity players to have shown interest in either or both of the portfolios.